Xencor, Inc. develops engineered antibody therapeutics for cancer and autoimmune diseases using its XmAb technology platform and related antibody-engineering formats. News about XNCR commonly covers clinical and preclinical updates for XmAb drug candidates, including TL1A programs such as XmAb942 and XmAb412, T-cell engaging bispecific antibodies such as XmAb819 and XmAb541, and presentations of data at medical meetings.
Recurring company updates also include quarterly financial results, research-and-development priorities, collaboration and licensing activity, intellectual-property developments tied to Xtend Fc domain technology, and royalty matters involving partner-marketed medicines such as Ultomiris.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on developing engineered monoclonal antibodies and cytokines for cancer and autoimmune diseases, will participate in a pre-recorded fireside chat at the H.C. Wainwright Bioconnect Virtual Conference.
The recording will be accessible starting January 10, 2022, at 4:00 a.m. PT under the 'Events & Presentations' section on the company’s website for a duration of at least 30 days.
Xencor currently has 22 candidates in clinical development utilizing its XmAb® technology.
Xencor, Inc. (NASDAQ:XNCR) announced updated data from its Phase 1 study of plamotamab, a bispecific antibody targeting B-cell non-Hodgkin lymphoma. Results will be presented at the ASH Annual Meeting. The drug showed encouraging clinical activity, with a recommended Phase 2 dose established at 50 mg every two weeks. The study demonstrated a 51% objective response rate, with 100% in patients with follicular lymphoma. A collaboration with Janssen aims to advance plamotamab development. The treatment was generally well tolerated, with manageable adverse events.
Xencor has granted Zenas BioPharma exclusive rights to develop and commercialize the investigational antibody obexelimab, aimed at treating autoimmune diseases. This agreement includes an upfront payment in the form of additional equity, with Xencor eligible for up to $480 million in milestone payments and royalties on future sales. Obexelimab is a bifunctional antibody with a unique mechanism that inhibits B-cell functions, demonstrating promising early clinical results.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered monoclonal antibodies and cytokines for cancer and autoimmune diseases, announced participation in two investor conferences. The Piper Sandler 33rd Annual Virtual Healthcare Conference is scheduled for November 22, 2021 at 10:00 a.m. EST. The Evercore ISI 4th Annual HealthconX Conference will take place on December 1, 2021 at 1:00 p.m. EST. Webcasts of these presentations will be available for 30 days on their website.
Xencor, Inc. (NASDAQ:XNCR) presented new data on its preclinical XmAb bispecific antibody programs and IL-12-Fc cytokine at the 36th Annual Meeting of the Society for Immunotherapy of Cancer. Highlights include the presentation of XmAb NK cell engagers and engineered IL-12 fusions showing strong anti-tumor activity with improved safety profiles. The company aims to submit an IND application for XmAb662 in 2022. These advancements underline Xencor’s innovative approach to drug development in oncology.
Xencor, Inc. (NASDAQ:XNCR) announced positive results from its Phase 1 trial of vudalimab, a PD-1 x CTLA-4 bispecific antibody, aimed at treating advanced solid tumors. The study, presented at the SITC meeting, showed vudalimab was generally well-tolerated with an objective response rate of 14.1%. Partial responses were noted in various cancers, including two in castration-resistant prostate cancer (CRPC). A complete response occurred in a patient with BRCA1+ ovarian cancer. Xencor plans to initiate Phase 2 studies for metastatic CRPC and advanced pelvic tumors.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, reported its third-quarter financials for 2021, revealing total revenue of $19.7 million, down from $35.4 million in 2020. The net loss widened to $40.2 million or $(0.69) per share, compared to a loss of $12.6 million or $(0.22) per share last year. Key developments include positive initial data from the Phase 1 study of XmAb306 and plans for upcoming presentations at major conferences. Looking ahead, Xencor expects to end 2021 with $575-$625 million in cash, supporting operations into 2025.
Xencor, Inc. (NASDAQ: XNCR) announced updated clinical data from its Phase 1 study of plamotamab, a bispecific antibody for treating B-cell malignancies, to be presented at the ASH Annual Meeting on December 12, 2021. The drug showed encouraging activity with an overall response rate (ORR) of 38.2% in diffuse large B-cell lymphoma and 80% in follicular lymphoma. Cytokine release syndrome was common but manageable. The company plans to initiate studies combining plamotamab with chemotherapy-free treatments starting late 2021 or early 2022.
Xencor, Inc. (NASDAQ:XNCR) announced updated results from its Phase 1 study of tidutamab, a bispecific antibody targeting neuroendocrine tumors (NETs). The study reported a recommended dosing regimen of 0.3 mcg/kg priming dose followed by 1.0 mcg/kg. At the data cut-off in August 2021, 41 patients were treated, with a 27% disease control rate. Tidutamab was well tolerated, with a low incidence of severe adverse effects. The drug is moving to a Phase 1b/2 study for Merkel cell carcinoma and small cell lung cancer, indicating potential advancements in treatment options.
Xencor, Inc. (NASDAQ:XNCR), a biopharmaceutical company specializing in engineered monoclonal antibodies and cytokines, has announced its participation in two investor conferences. The Credit Suisse 30th Annual Healthcare Conference will feature a presentation on November 9 at 2:40 p.m. ET. Additionally, the Jefferies London Healthcare Conference will have an on-demand presentation available starting November 18 at 8:00 a.m. GMT. Webcasts will be accessible on the company's website, with replays archived for at least 30 days.